Please use this identifier to cite or link to this item:
|Title:||Nano-immuno assay development for the detection of cancer biomarkers||Authors:||Ambrosetti, Elena
|Keywords:||AFM; nano-immuno assay; cancer biomarker||Issue Date:||2014||Publisher:||EUT Edizioni Università di Trieste||Source:||Elena Ambrosetti, Alessandro Bosco, Loredana Casalis, Nano-immuno assay development for the detection of cancer biomarkers, in S. Passamonti, S. Gustincich, T. Lah Turnšek, B. Peterlin, R. Pišot, P. Storici (Eds.), Cross-border Italy-Slovenia biomedical research: are we ready for horizon 2020? Conference proceedings with an analysis of innovation management and knowledge transfer potential for a smart specialization strategy. Trieste, EUT Edizioni Università di Trieste, 2014, pp. 111-114||Abstract:||
The quantitative analysis of protein markers is a promising strategy in diagnosis, prognosis and
therapy monitoring of malignant tumors. The optimization of the clinical detection of these markers is directed
towards the use of a small volume system.
We developed a multiplexing nano-immuno array for proteomic analysis in low sample volumes with potential
capability of pathological screening of cancer biomarkers.
Nanografting, a tip assisted Atomic Force Microscopy (AFM) nanolithography technique is used to fabricate
DNA nanoarrays. DNA nanospots created by nanografting are exploited in order to immobilize DNA-antibody
conjugates that recognize specific proteins of interest.
The determination of the antigen content of a biological sample was obtained from the analysis of AFM
topographic profiles of the nanopatches before and after the incubation.
As a proof of principle, we focused on the biomarker Human Epidermal Growth Factor Receptor 2 (Her2),
relevant antigen found in some human cancers such as breast, lung and gastric ones.
By measuring spot height variation we performed the detection of low concentrations of the biomarker and we
were able to optimize the device sensitivity by correlating the density of the DNA-antibody conjugates on the
surface and their capability to bind the Extra Cellular Domain (ECD) of Her2.
As future perspectives we are also exploring the use of new binders, as aptamers and nanobodies (VHH), as
new tool for the recognition of specific biomarkers with higher affinity.
|Appears in Collections:||Trans2Care, 2014. Cross-Border Italy-Slovenia Biomedical Research. Are we ready for Horizon 2020?|
Show full item record
Page view(s) 20875
checked on Aug 11, 2022
checked on Aug 11, 2022
This item is licensed under a Creative Commons License